A Randomised, Double-Blind, Parallel- Group, Multicentre, Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/ Daily or Placebo) With Fulvestrant (Loading Dose), In Postmenopausal Advanced Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Vandetanib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ZACFAST
- 02 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.